Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca Australia
  • Ono Pharmaceutical
  • Bristol-Myers Squibb
  • Japan Agency for Medical Research and Development
  • Chugai Pharmaceutical

This publication has 55 references indexed in Scilit: